Relapsed/Refractory Chronic Lymphocytic Leukemia: The Evolving Role of BTK Inhibitors
Listen now
Description
Did you know that the National Comprehensive Cancer Network (NCCN) guidelines now include an investigational noncovalent BTK inhibitor for the treatment of relapsed/refractory CLL?
Credit available for this activity expires: 12/05/24
Earn Credit / Learning Objectives & Disclosures:
https://www.medscape.org/viewarticle/998747?ecd=bdc_podcast_libsyn_mscpedu
More Episodes
Do you know the best way to manage your patients with newly diagnosed advanced ovarian cancer?
Credit available for this activity expires: 4/23/25
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000702?ecd=bdc_podcast_libsyn_mscpedu
Published 04/25/24
Published 04/25/24
Join our expert panel as they discuss the role of Janus kinase (JAK) inhibitors in the treatment of axial spondyloarthritis (axSpA).
Credit available for this activity expires: 4/24/25
Earn Credit / Learning Objectives & Disclosures:...
Published 04/25/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
